Co-crystallization, as a crystal-engineering technique, is generating a great interest in the pharmaceutical industry. Co-crystals incorporate pharmaceutically acceptable guest molecules into a crystal lattice along with the API, resulting mainly in renewed physico-chemical properties.
SARA PHARM’s co-crystal screen is designed to identify new solid forms with enhanced physico-chemical property or bioavailability enabling in this way the development of improved versions of existing drug products. SARA PHARM can offer several levels of co-crystal screening to suit different research goals and budgets. In this particular case as well SARA PHARM is using its comprehensive database of co-crystal formers with their fully described physico-chemical properties.